Understanding and Harnessing Therapy-Induced Senescence to Treat Ovarian Cancer
Abstract
Conventional therapies for high-grade serous ovarian cancer (HGSC) often fail to eradicate tumors. The residual cancer cells that survive treatment can enter a state known as therapy induced senescence (TIS). Despite TIS being a state of cell cycle arrest, TIS can have potentially adverse effects underpinning the development of treatment-resistant recurrent disease. Harnessing the properties of senescent cells can lead us to devise new therapeutic strategies that prevent recurrence, but little is known about TIS in HGSC. To better understand TIS in HGSC, we are using a suite of human and patient-derived cell lines and immune-competent model systems. We have performed gene expression and proteomic profiling of TIS HGSC cells and identified candidate targets involved in their cell survival and escape. We have also performed genetic and drug screens to highlight potential strategies for both re-instating cell cycle arrest in cells that have escaped TIS and eradicating senescent HGSC cells. The next phase of the project will involve validating these targets and identifying in vivo approaches to exploit TIS for HGSC therapy.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2023
- Accession Number
- AD1214909
Entities
People
- Keefe Chan
Organizations
- University of Melbourne